Evidence map›Paper›PMID 40253664›Full record

ArticleDermatology and therapy2025

Canadian Consensus Guidelines for the Management of Vitiligo.

Vimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, Julien Ringuet, Irina Turchin, H Chih-Ho Hong, Charles Lynde, Kim A Papp, Jensen Yeung, Melinda J Gooderham

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Vitiligo-Current Treatment Options and Future Perspectives.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vimal H PrajapatiDivision of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
Harvey LuiDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Yvette Miller-MonthropeDivision of Dermatology, Temerty School of Medicine, University of Toronto, Toronto, ON, Canada.
Julien RinguetCentre de Recherche Dermatologique du Québec Métropolitain, Quebec City, QC, Canada.
Irina TurchinProbity Medical Research, Waterloo, ON, Canada.
H Chih-Ho HongDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Charles LyndeLynde Institute for Dermatology, Markham, ON, Canada.
Kim A PappDivision of Dermatology, Temerty School of Medicine, University of Toronto, Toronto, ON, Canada.
Jensen YeungDivision of Dermatology, Temerty School of Medicine, University of Toronto, Toronto, ON, Canada.
Melinda J GooderhamSKiN Centre for Dermatology, Peterborough, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitiligo remains a highly burdensome disease associated with significant autoimmune and psychosocial comorbidities. Although the therapeutic landscape has long been dominated by off-label therapy, new treatments are emerging. Limited guidance on how to safely and effectively utilize available therapies poses challenges for healthcare providers. Herein, we provide generally accepted principles, consensus recommendations, and a treatment algorithm for the management of vitiligo, as developed by a panel of ten Canadian dermatologists with expertise in managing vitiligo.

methodsThe three-phase process consisted of identifying themes and research questions; conducting a systematic literature review; and discussing/voting on generally accepted principles, consensus statements, and a treatment algorithm using an iterative consensus process.

resultsExperts agreed to 27 generally accepted principles, ten consensus statements, and a treatment algorithm. Education about vitiligo pathogenesis and repigmentation biology can help patients, caregivers, and healthcare providers set realistic expectations for treatment. Treatment should focus on repigmentation or stabilizing progression, rather than on depigmentation. Topical therapies include topical corticosteroids, topical calcineurin inhibitors, and the topical Janus kinase inhibitor ruxolitinib cream. Phototherapy, such as narrow-band ultraviolet B and excimer laser/lamp, can be used as monotherapy or in combination with other treatments. Off-label systemic therapies may be appropriate for patients with unstable or rapidly progressing disease. Surgical therapy may be suitable for patients with localized or stable recalcitrant disease. Maintenance therapy may help mitigate the risk of disease relapse.

conclusionImproved clarity around the benefits, risks, and limitations of available therapies has supported the development of robust guidelines and a treatment algorithm for vitiligo. Disease stabilization and repigmentation are goals that can largely be achieved, particularly when patients share a mutual understanding of vitiligo and its treatment options. A Graphical Abstract is available for this article.

Indexed as

GuidelinesJanus kinase inhibitorPhototherapyTopical calcineurin inhibitorTopical corticosteroidVitiligo

Identifiers

PMID40253664
PMCPMC12092322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.